摘要:
Two crystal forms of (R)-3-[2-(2-amino-5-trifluoromethoxybenzamido)acetamido]-1-(6-methylindol-3-ylmethyl)pyrrolidine which exhibit specific X-ray powder diffraction patterns or infrared absorption spectra, amorphous form thereof, a pharmaceutical composition containing the crystal or amorphous form as an active ingredient, as well as methods for preparing them are provided.
摘要:
A production method of an acetamidopyrrolidine derivative or a salt thereof comprising the reaction steps represented by the following formula: wherein R1 represents a hydrogen atom or a C1-C6 alkyl group; R13, R14, R15 and R16 each represent independently a hydrogen atom, a halogen atom, a C1-C6 alkyl group, a C1-C6 alkoxy group, a hydroxyl group, a C1-C6 haloalkyl group or a C1-C6 haloalkoxy group; and R21 represents an ester-type protecting group.
摘要翻译:一种乙酰胺基吡咯烷衍生物或其盐的制备方法,包括由下式表示的反应步骤:其中R 1表示氢原子或C 1 -C 3 > 6个烷基; R 13,R 14,R 15和R 16各自独立地表示氢原子,卤素原子, C 1 -C 6烷基,C 1 -C 6烷氧基,羟基,C 1 -C 6烷基,C 1 -C 6烷基, C 1 -C 6卤代烷基或C 1 -C 6 -C 6卤代烷氧基; C 1 -C 6卤代烷基或C 1 -C 6 - R 21表示酯型保护基。
摘要:
There is provided an industrial production method of an aminopyrrolidine derivative having chemokine receptor antagonist activity represented by the following formula, a synthetic intermediate thereof and a production method thereof: wherein R11 is H, C1-C6 alkyl or C2-C7 alkanoyl; R12, R14, R15, R16 and R17 are H, halogen, optionally halogenated C1-C6 alkyl, optionally halogenated C1-C6 alkoxy, hydroxyl or C2-C7 alkoxycarbonyl; R23, R24, R25 and R26 are H, halogen, optionally halogenated C1-C6 alkyl, optionally halogenated C1-C6 alkoxy or hydroxyl; and R3 is H or C1-C6 alkyl.
摘要翻译:提供了具有下式表示的趋化因子受体拮抗剂活性的氨基吡咯烷衍生物及其合成中间体及其制备方法的工业生产方法:其中R 11是H,C 1 C 6 -C 6烷基或C 2 -C 7烷酰基; R 12,R 14,R 15,R 16和R 17均为 H,卤素,任选卤代C 1 -C 6烷基,任意卤代C 1 -C 6烷氧基, 羟基或C 2 -C 7烷氧基羰基; R 23,R 24,R 25和R 26是H,卤素,任选卤代的C 1 -C 12烷基, C 1 -C 6烷基,任选卤代C 1 -C 6烷氧基或羟基; R 3是H或C 1 -C 6烷基。